BioSpace News Archive

Immunocore Holdings plc announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to investigate Immunocore’s ImmTAC bispecific TCR candidate targeting PRAME HLA-A02, IMC-F106C, in combination with Bristol Myers Squibb’s nivolumab, in first-line advanced cutaneous melanoma.

AC Immune SA announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer’s and Parkinson’s Diseases, taking place in Lisbon, Portugal March 5-9, 2024.

NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023.

Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2023.

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024, at 2:10 p.m. ET.

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”) today announced that data from the Phase 2 trial of VTX002 in ulcerative colitis will be presented during the 19th Congress of the European Crohn’s and Colitis Organisation (ECCO) on February 22, 2024, in Stockholm, Sweden.

C4 Therapeutics, Inc. today reported financial results for the year ended December 31, 2023, as well as recent business updates.

Chimerix (NASDAQ:CMRX) today announced that it will host a live conference call and audio webcast on Thursday, February 29, 2024 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2023, and to provide a business overview.

Rhythm Pharmaceuticals, Inc. announced plans to add a cohort of patients with hypothalamic obesity in Japan to its ongoing global Phase 3 clinical trial of setmelanotide, with dosing expected to begin in the third quarter of 2024.

SpringWorks Therapeutics, Inc. today announced that management will present at the following investor conferences.